Reportstack has announced a new market report on Lu AE58054 (Alzheimer’s Disease) - Forecast and Market Analysis to 2022. There are no long-term effective therapies for Alzheimer’s Disease (AD), so this remains at the top of the list for unmet needs. While physicians agree that symptomatic therapies are relatively safe and effective, these therapies are still lacking because of they cannot maintain their effects and lack mechanisms that alter the course of the disease.
Lu AE58054 is a selective serotonin 5-HT6 receptor antagonist under development by H. Lundbeck and its partner Otsuka Pharmaceutical. 5-HT6 receptors have become an attractive target in research on cognitive disorders after the discovery that instead of acting on the dopaminergic system, 5-HT6 activation enhances cholinergic excitatory neurotransmission (Upton et al., 2008).
Scope
- Overview of AD, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Lu AE58054 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Lu AE58054 for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for AD
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Lu AE58054 performance
- Obtain sales forecast for Lu AE58054 from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).
Lu AE58054 is a selective serotonin 5-HT6 receptor antagonist under development by H. Lundbeck and its partner Otsuka Pharmaceutical. 5-HT6 receptors have become an attractive target in research on cognitive disorders after the discovery that instead of acting on the dopaminergic system, 5-HT6 activation enhances cholinergic excitatory neurotransmission (Upton et al., 2008).
Scope
- Overview of AD, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Lu AE58054 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Lu AE58054 for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for AD
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Lu AE58054 performance
- Obtain sales forecast for Lu AE58054 from 2012-2022 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).
To view the table of contents and know more details please visit Lu AE58054 (Alzheimer’s Disease) - Forecast and Market Analysis to 2022 report.
Similar Reports:
No comments:
Post a Comment